Background-A recent association study identified a common variant (rs9790517) at 4q24 to be associated with breast cancer risk. Independent association signals and potential functional variants in this locus have not been explored.
Introduction
A common genetic variant at 4q24, rs9790517, was recently identified to be associated with breast cancer risk, through a combined analysis of genome-wide association studies (GWAS) together with data from a large association study using a custom array, iCOGS (1, 2). This risk variant, termed subsequently as the index SNP in this paper, is located in intron 11 of TET2, a chromatin-remodeling gene that functions as a tumor suppressor. TET2 has been found to be frequently somatically mutated in multiple cancers, including breast cancer (3) (4) (5) (6) (7) (8) (9) . However, the index SNP is located in a region with no evidence of functional significance. The initial GWAS reported only the most strongly statistically associated SNP in this region, although many other SNPs at the same locus also may be associated with breast cancer risk, one or more of which are causally related to breast cancer risk.
Comprehensive fine-scale mapping may help to identify the variants most likely to be functionally related to risk, and may enable the identification of additional independent signals.
Dense fine-scale mapping of GWAS-identified loci has successfully identified novel putative causative variants for several common diseases, including breast cancer (10) (11) (12) (13) (14) (15) (16) (17) . For example, previous fine-mapping studies of 5p15, 20q16, 2q35, 5q11 and 11q13 have identified multiple independent risk signals as well as potential causative variants in each region, using data from the Breast Cancer Association Consortium (BCAC) (12, 13, 16, (18) (19) (20) . The index SNP (rs9790517) at 4q24 is close to another SNP, rs7679673 (r 2 = 0.42, 23 kb apart), which has been associated with prostate cancer (21) . In this fine-mapping project, a dense set of SNPs in this 4q24 region was genotyped in genomic DNA samples obtained from 106,708 participants included in the BCAC. We then analyzed data from 3,912 genotyped and imputed SNPs in this region in an attempt identify potential functional variants that may explain the observed association of genetic variants in this locus with breast cancer risk.
Materials and Methods

Study populations
The study included 55,540 breast cancer cases and 51,168 controls from 50 studies participating in the BCAC. Details of the studies, sample selection, and genotypes are described elsewhere (1) . The dataset included 39 studies from European-ancestry populations (48, 155 cases and 43,612 controls), nine from Asian populations (6,269 cases and 6,624 controls) and two from populations of African ancestry (1,116 cases and 932 controls).
Genotyping of 4q24
A dense set of SNPs at 4q24 were selected for genotyping on iCOGS based on evidence of a prostate cancer associated SNP, rs7679673 (17) , since at the time of the assay design this region had not yet been linked to breast cancer risk. An interval of 596kb (positions in chr4, 105932103 -106528262 from hg19) was identified based on all SNPs with r 2 > 0.1 with the SNP rs7679673 based on HapMap 2 CEU (22) . All SNPs in the interval were then identified from the 1000 Genomes Project CEU (April 2010)(23), together with HapMap 3, and we selected SNPs for genotyping which had an MAF > 2% in Europeans and an Illumina Design score > 0.8. From this set, all SNPs with r 2 > 0.1 with SNP rs7679673 were selected, together with an additional set of SNPs to tag the remaining SNPs at r 2 > 0.9. In total, 490 SNPs were successfully genotyped and passed quality control. We imputed genotypes for the remaining SNPs using the program IMPUTE2 (24) and the March 2012 release of the 1000 Genomes Project as a reference. Those imputed SNPs with common SNPs (MAF > 0.02) and imputation r 2 > 0.3 were included in the current analysis.
Statistical analyses
For each genotyped and imputed SNP, we evaluated its association with breast cancer risk using a logistic regression model with adjustment for age, study site and principal components to correct for potential population stratification (the first six principal components, plus one additional principal component for the LMBC in analyses of the European ancestry data, or the first two principal components in the analyses of the Asian and African ancestry data), as previously described (1) . Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated under a log-additive model. We conducted separate analyses within European, Asian and African American populations.
To identify independent association signals, we performed stepwise forward logistic regression analyses for the associated SNPs with an MAF > 0.02 showing association at p < 1 × 10 −4 in the single marker SNP analysis. We used the Step function implemented in the R package (25) with the penalty K = 10 for inclusion of additional SNPs in the model. Since no SNPs showed p < 1 × 10 −4 in the Asian or African populations, this analysis was performed only in the European population. The model was adjusted for the same factors as in the single SNP analysis. To define potentially causative variants, we computed a likelihood ratio for each SNP relative to the best associated SNP in each signal and excluded SNPs with a likelihood ratio < 1/100. Haplotype-specific ORs were estimated using haplo.stats in R, including age, study site, and the first six principal components, plus one additional principal component for the LMBC study.
Functional annotation
We annotated 29 candidate causative variants for potential functional significance using chromHMM annotation across nine ENCODE(26) cell lines: HMEC, GM12878, H1-hESC, K562, HepG2, HSMM, HUVEC, NHEK, and NHLF (27) . For each variant, we investigated whether it is mapped to functional regions (i.e. promoter and enhancer) through chromatin states annotation from the UCSC Genome Browser (28) . The epigenetic landscape of histone markers H3K4Me1, H3K4Me3, and H3K27Ac was also examined through layered histone tracks on seven ENCODE cell lines including GM12878, H1-hESC, K562, HSMM, HUVEC, NHEK, and NHLF from the UCSC Genome Browser. DNase I hypersensitive and TF ChIP-Seq datasets were investigated in all available ENCODE cell lines, including breast normal cell line, HMEC, and breast cancer cell lines, T-47D and MCF-7. Two publicly available tools, RegulomeDB (29) and HaploReg v2 (30) , were also used to evaluate those likely functional variants (9, 31) . In addition, we also investigated whether each variant is overlapped with regulatory elements of enhancers and TSS from two previous studies including Hnisz et al (32) and Andersson et al (FANTOM5 project) (33) . Chromatin Interaction Analysis by Paired End Tag (ChIA-PET) (mediated by RNA polymerase 2) data from MCF7 cell were downloaded from GEO (GSE39495) and the ggbio R package was used to represent the interactions between cell enhancers (containing a strongly associated variant) and a predicted gene promoter.
TCGA data resource and eQTL analysis
We downloaded RNA-Seq V2 data (level 3) of 1,006 breast cancer tumor tissues from the TCGA data portal (34) . DNA methylation data measured by the Illumina HumanMethylation450 BeadChip were also retrieved from TCGA level 3 data. We also downloaded level 3 SNP data genotyped using the Affymetrix SNP 6.0 array. Copy Number Alteration (CNA) data for genes PPA2, ARHGEF38, INTS12, GSTCD and TET2 at 4q24 for TCGA samples were collected from the CbioPortal (35) . We analyzed a total of 645 breast tumor tissues in Caucasian population including matched CNV, genotype and expression data.
We performed eQTL analysis in TCGA tumor tissues described above. We applied several steps to reduce the batch or other technical effects on gene expressions following the approach described by Pickrell et al (36) . First, the RNA-Seq by Expectation-Maximization value of each gene was log2 transformed and those genes with a median expression level of 0 across tissues were removed. We then performed the principal component correction on gene expression to remove potential batch effects. A linear regression of expression values on the first five principal components was constructed and the residuals were used to replace the expression values of each gene among tissues. To make the data better conform to the linear model for the eQTL analysis, we further transformed the gene expression levels to fit quantiles of N(0, 1) distribution based on the ranks of the expression values to their respective quantiles. Residual linear regression models were constructed to detect eQTLs, while adjusting for methylation and CNA, according to the approach used by Li et al (37) .
We also extracted matched genotypes and gene expression levels as described above in a total of 135 tumor-adjacent normal breast tissues in European ancestry individuals from the METABRIC project (38) . Gene expression profiling was generated on the Illumina HT12 v3 microarray platform and probe-level measurements were used. Genotyping was performed on the Affymetrix SNP 6.0 with genotypes being imputed using the 1000 Genomes March 2012 CEU reference panel. Matrix eQTL was performed for evaluating the association between genotypes and gene expression levels (39) .
Results
Association Analyses
We evaluated associations for 490 genotyped and 3,422 well-imputed SNPs at 4q24 spanning 596 kb (positions in chr4: 105932103 -106528262 from hg19) in 48,155 cases and 43,612 controls of European descent. A total of 29 variants were significantly associated with breast-cancer risk at p < 1 × 10 −4 ( Figure 1 , Supplementary Table 1) . Of these, 15 variants were directly genotyped and 14 were imputed with r 2 > 0.9. All risk-associated variants had minor allele frequencies (MAF) > 0.05. The index SNP, rs9790517, showed strong evidence of a significant association with breast cancer risk (OR = 1.05; 95% CI 1.03-1.08; p = 5.44 × 10 −6 ), which was consistent with the report from the original study (1) . The strongest association was, however, found for an imputed SNP rs73838678 (OR =1.12, 95% CI 1.07-1.17; p = 1.29 × 10 −6 ).
To identify potential independent association signals, we carried out forward stepwise logistic regression analysis on SNPs associated with breast cancer at p < 1 × 10 −4 . Two independent association signals were revealed: index SNP rs9790517 (conditional p = 2.51 × 10 −4 , after adjustment for the SNP in the second signal) and SNP rs77928427 (conditional p = 1.86 × 10 −4 after adjusting for the index SNP) ( Table 1 ). The index SNP rs9790517 in signal 1 was in weak LD with the SNP rs77928427 in the second risk signal (r 2 = 0.04). These two SNPs are more than 300kb from each other.
We performed similar analyses, restricting to cases with estrogen receptor positive (ER+) cancer and identified 17 variants associated with ER+ breast cancer risk at p < 1 × 10 −4 in women of European ancestry. No SNP was found to be associated with ER-negative (ER−) disease at p < 1 × 10 −4 . However, the per-allele ORs for the two SNPs independently associated with overall breast cancer risk were similar for ER− and ER+ disease (Table 1 ; all tests of heterogeneity by ER-status p > 0.10). Conditional analysis yielded similar associations for ER+ breast cancer to those for overall breast cancer for the two independently associated SNPs.
We performed haplotype analysis based on the top SNPs from the two signals: rs9790517 and rs77928427 in European descendants. Three major haplotypes were observed. Compared with the most common haplotype carrying the common allele at both SNPs, haplotype TA carrying two risk alleles showed the strongest association with breast cancer risk (OR = 1.11; 95% CI 1.07-1.15; p = 2.31 × 10 −8 ) ( Table 2 ). The frequency of this haplotype was 9.4%. Haplotypes CA and TC, carrying the risk allele in either signal 1 or 2, also were associated with elevated risk of breast cancer, although the association was only marginally significant. Thus, the haplotype analyses were consistent with the hypothesis that there are two independently associated variants in the region.
We compared the average age among those cases carrying risk and non-risk alleles of rs9790517. Interestingly, we observed that the cases carrying risk alleles were slightly younger than those carrying non-risk alleles (average age: 57.54, 57.62 and 57.64 respectively for patients carrying alleles TT, TC and CC of rs9790517; p < 2 × 10 −16 ). No such pattern was observed for rs77928427.
We carried out association analysis for all SNPs with breast cancer in subjects of Asian and African descent. None of the SNPs identified in women of European ancestry as associated at p < 10 −4 showed a significant association in either Asians or African women at p < 0.05 (Table 3) . However, the 95%CI for the OR estimates in Asians and Africans included the point estimate in Europeans for both of the two top independent SNPs. We found one SNP associated with breast cancer risk in Asians and three in Africans, at p < 0.01 (strongest signal rs1116764: OR 1.10; 95% CI 1.04-1.16; p = 4.21 × 10 −4 ), none of these SNPs were in LD with the two independent association signals identified in European women (Table 3) .
Functional Annotation
We used a likelihood ratio > 1:100 relative to the best associated SNP in each signal to select candidate variants for functional annotation in order to identify potentially causative variants in this region (Supplementary Table 1 ). In total, 29 SNPs were identified including 24 for signal 1 and 5 for signal 2. Of these, 17 SNPs in signal 1 were strongly correlated with the original index SNP rs9790517, and the remainder were more weakly correlated. All SNPs were evaluated using DNase-Seq and ChIP-Seq data from the ENCODE project. The most promising evidence for functionality was found for SNPs rs62331150 and rs73838678, both in LD with rs9790517 (r 2 = 0.98 and r 2 = 0.09, respectively) in signal 1.The annotation from chromatin states (27) revealed that rs62331150 resides an active promoter region, and rs73838678 in a strong enhancer region, on several ENCODE cell lines including HMEC (Human Mammary Epithelial Cell) but not for other SNPs in either signal 1 or 2 ( Figure  2A ). The active promoter associated histone marks (H3K4Me3 and H3K27Ac) and enhancer associated histone marker H3K27Ac were enriched in the intervals containing rs62331150 and rs73838678, respectively, in several ENCODE cells, and both SNPs were also found to be located in or near a DNase I hypersensitive site (DHS) (Figure 2A, B) . In addition, both variants were found to overlap with predicted enhancer regions of TET2 in multiple cells including HMEC as reported in a recent study (32) . None of the other SNPs in signal 1, and none of the 5 SNPs in signal 2 fell into a strong annotated promoter or enhancer region in those cells.
To identify putative gene targets, we examined the annotation of TSS and TSS-associated enhancers using Cap Analysis of Gene Expression (CAGE) from the FANTOM5 project (23). We found that rs62331150 and rs73838678 reside in regulatory elements of enhancers associated with transcription start sites (TSS) and TSS of TET2 in multiple cells ( Figure  2A ). We also examined potential functional chromatin interactions between distal and proximal regulatory transcription-factor binding sites and the promoters at the risk regions using ChIA-PET data. ChIA-PET data for Pol2 in MCF-7 breast tumor derived cells showed multiple chromosomal interactions across the entire region, but these interactions were particularly dense in the vicinity of the TET2 promoter region, encompassing the strongest candidate causal variant rs62331150 and rs73838678 ( Figure 2A ).
A search of RegulomeDB indicated that rs62331150 and rs73838678 were annotated to lie in the breast cancer related transcription factor (TF) SP1 (Specificity Protein 1) and PR (progesterone receptor) (40, 41) predicted binding motifs, respectively ( Figure 2B ). We observed that the G nucleotide was more frequently found in the SP1 motif than the T nucleotide, indicating that the SP1 may preferentially bind to the reference G allele ( Figure  2B ). For variant rs73838678, no significant allelic frequency difference in the PR motif was observed. Using ChIP-Seq data from a total of 161 TFs from the ENCODE project (ChIPSeq V3), we found that both variants are located in multiple TF binding sites ( Figure 2B ).
As an example, ChIP-Seq binding peaks of breast cancer-related TFs, EGR1 and NIFC, harbor the variant rs62331150 and rs73838678, respectively (42, 43) . In particular, we observed that P300, marking the active enhancer, was found to bind close to both variants in multiple ENCODE cell lines, suggesting that the variant in the region may lead to TET2 transcriptional activation.
Gene expression analyses
We used both The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) data to examine the association of the putative functional SNP rs62331150 and rs73838678 with expression of TET2 and several other neighboring genes, including PPA2, ARHGEF38, INTS12, and GSTCD, in breast cancer tissues. No significant correlations with any genes were observed for variant rs73838678. Variant rs62331150 was weakly correlated with TET2 expression in both datasets (p = 0.039 and p=0.025 respectively for TCGA and METABRIC), the reference allele G being associated with increased expression relative to the risk allele T (Figure 3) . The result was consistent with the observation from our functional annotation that SP1 may preferentially bind to the reference G allele, leading to a significant increase in TET2 transcription activation. No correlation between rs62331150 and the expression of any other gene in the region was found in either dataset. Overall, our findings supported a hypothesis that TET2 is the target gene for the signal 1 association, and that the association with breast cancer risk may be mediated through regulation of TET2 gene expression. The result is also in line with previous findings that TET2 functions as a tumor suppressor and its high expression level may reduce breast cancer risk (44, 45) .
Discussion
In this study, we identified two independent association signals at 4q24 in women of European ancestry. Statistical analyses reduced the set of likely causative variants to 29.
Using functional genomic data, we provided strong evidence for two variants as functional variants. Our study suggests that the breast cancer risk may be mediated through their regulation of TET2 gene expression.
In our initial single marker analysis, we observed that the majority of variants, including the index SNP, were located in or near the TET2 gene region. Through eQTL analysis based on TCGA data, we found that multiple SNPs in signal 1 were correlated with TET2 expression, which was expected given their strong LD with each others. Of those SNPs, rs62331150 resides in the promoter of TET2. Although eQTL analysis is helpful to identify potential target genes, it is difficult to use eQTL results to pinpoint the causal variant particularly when multiple SNPs are in strong LD. In addition to residing in the promoter region of the TERT2, the variant rs62331150 was also found to be located in the binding sites of multiple TFs including the breast cancer related TF EGR1, potentially affecting the binding affinities of specific TFs. Interestingly, the putative functional SNP rs62331150 is close to SNP rs7679673 that has been associated with prostate cancer risk (21) , indicating that TET2 gene may also be involved in prostate cancer risk. In comparison to rs62331150, rs73838678 in signal 1 was not found to have a significant association with TET2 and any other nearby genes. One possible reason is that the statistical power is low for rs73838678 due to its relative low allele frequency (MAF = 0.049). We also could not exclude the other possible target genes for rs73838678. Future studies using in vitro and in vivo assays are warranted to verify this conclusion.
Cumulative evidence shows that TET2 has an important function in tumor suppression. This gene can alter the epigenetic status of DNA base methylcytosine to 5-hydroxymethylcytosine and therefore, have a genome-wide scale of influence on gene expression (46) (47) (48) . Accordingly, TET2 gene dysregulation could cause aberrant DNA methylations and consequently contribute to cancer development (3-6, 45, 49) . Here, we reported TET2 as a candidate susceptibility gene for both ER+ and ER− breast cancer types. Although the associations for the top SNPs, rs9790517 and rs77928427, with breast cancer risk in Asian and African-ancestry populations were not statistically significant, likely due to a small sample size, the direction of the associations was mostly consistent in all population, suggesting that the TET2 gene play a similar role in the etiology of breast cancer in all three populations.
Although our fine-mapping analysis represents the most comprehensive analysis of variants at 4q24 thus far, many SNPs, particularly rare variants, cannot be imputed. Deep sequencing of this region may reveal additional risk variants for breast cancer. For example, rs76682196, located 884 bp upstream of rs62331150, was found to be potentially functional using the ENCODE data. The variant is present in DHS and TFs sites. In particular, it lies in the ER (Estrogen Receptor-) predicted binding motif and ChIP-Seq peak in breast cancer cell line T-47D. However, this variant was not included in the study due to its low frequency (MAF < 0.01) in populations from all three ethnic groups.
In conclusion, this dense fine-mapping study identified two independent association signals with breast cancer risk at 4q24, increasing the estimated familial relative risk of breast cancer explained by this locus from the original 0.07% to 0.15% among women of European descent. Functional analyses revealed one potentially functional variant, rs62331150. The risk allele is associated with lower expression of TET2, consistent with previous findings that this gene acts as a tumor suppressor. A) The index SNP rs9790517 is plotted in diamond purple. The LD (r 2 ) for the index SNP with each SNP was computed based on European ancestry subjects included in the 1000 Genome Mar 2012 EUR. P values were from the single-marker analysis based on logistic regression models after adjusted for age, study sites and the first six principal components plus one additional principal component for the LMBC in analyses of data from European descendants. The plot was generated using LocusZoom (50). layered histone modifications from the same ENCODE cell line are shown in the same color (The detailed color scheme for each ENCODE cell line described in the UCSC genome browser). The red and orange colors in chromatin states refer to active promoter and strong enhancer regions, respectively (The detailed color scheme of the chromatin states described in the previous study (27) The reference allele G of rs62331150 is significantly associated with the increased gene expression relative to the risk allele T. c r 2 for linkage disequilibrium with the index SNP rs9790517.
d Adjusted for age, study and the first six and an additional PC for LMBC study.
e Included both top SNPs and adjusted for other top SNPs, age, study sites and the first six and an additional PC for LMBC study.
f A total of 23 SNPs cannot be excluded using LR < 1/100 as candidate causal variants (see Supplementary table 1) .
g A total of 4 SNPs cannot be excluded using LR < 1/100 as candidate causal variants (see Supplementary table 1) Author Manuscript Author Manuscript Author Manuscript Author Manuscript Table 2 Haplotype analyses of the lead SNPs in two independent signals in relation to breast cancer risk among women of European ancestry. Abbreviations: OR, odds ratio; CI, confidence interval.
a Index SNP.
b Haplotype frequency.
c Adjusted for age, study and the first six PCs and an additional PC for LMBC study.
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Author Manuscript Author Manuscript Author Manuscript Author Manuscript Table 3 Association of lead SNPs identified in women of European and non-European descent with breast cancer risk among women of Asian (6, c r 2 for linkage disequilibrium with the index SNP rs9790517 in Asians and Africans, respectively.
d Adjusted for age, study and the first six PC and an additional PC for LMBC study.
